drugset / Trial / NCT03068429

Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.

NCT03068429

Phase 4 Completed 69 enrolled University of Sao Paulo
NaSingle-groupOpen-labelOther

Summary

24 OCD patients and 24 healthy subjects will be submitted to a two-day fear conditioning paradigm during acquisition of functional magnetic resonance imaging (fMRI). OCD patients will be submitted to the paradigm at two timepoints: baseline and 4 weeks after treatment initiation with sertraline up to 200mg/day or maximum tolerated dosage. OCD patients are expected to demonstrate worsened extinction retention compared to healthy subjects at baseline. Sertraline treatment is expected to improve extinction retention compared to baseline and to normalize the brain regions being recruited with the conditioned stimuli presented during the recall phase.

Timeline

Start
2016-12-01
Primary completion
2019-12-20
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sertraline Small molecule 200 mg